PSNL News and Press, Personalis Inc. From 08/12/20

Personalis (NASDAQ: PSNL ) has priced its public offering of 6,578,947 common stock at $19/share, for expected gross proceeds of $125M . More news on: Personalis, Inc., Healthcare stocks news, , Read more ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announced underwritten public offering of 6,578,947 shares of its common stock at a price to the public of $19.00 per share. Gross proceeds to Per...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten public offering of $100 million of its common stock. In addition, Personalis expects the underwriters to be granted a 30-day option to pur...

Personalis, Inc. (PSNL) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Partici...

Personalis (NASDAQ: PSNL ) : Q2 GAAP EPS of -$0.29 beats by $0.05 . More news on: Personalis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2020. Second Quarter Highlights Reported record revenues of $19.5 million in the second quarter of 2020 versus $15.8 million in the sec...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients. NeXT Liquid Biopsy, paired with P...

Precision medicine is a new approach to disease management and treatment that takes into account the genetic makeup, lifestyle and environment of each individual patient. The healthcare industry is shifting from a one-size-fits-all approach to a focus on precision medicine, which allows physic...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020. In conjunction with the release, the Company will host a conference call and webcast that d...

Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced that, effective on July 15, 2020, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 44,600 shares of its common stock and restricted sto...